Statin — HMG-CoA Reductase Inhibitor
Pregnancy: Contraindicated in pregnancy
Simvastatin
Brand names: Zocor
Adult dose
Dose: 10-40 mg once daily
Route: Oral
Frequency: Once daily (evening)
Max: 40 mg/day (80 mg no longer routinely used due to rhabdomyolysis risk — MHRA 2012)
Evening administration optimises efficacy (cholesterol synthesis peaks at night)
Paediatric dose
Dose: Seek specialist opinion N/A/kg
Route: Oral
Frequency: Seek specialist opinion
Max: Seek specialist opinion
Seek specialist opinion
Dose adjustments
Renal
Start at 5-10 mg if eGFR under 30; increase cautiously with monitoring
Hepatic
Contraindicated in active liver disease
Paediatric weight-based calculator
Seek specialist opinion
Clinical pearls
- MHRA 2012 safety alert: Simvastatin 80 mg associated with increased myopathy risk — 80 mg should only be used in patients already tolerating it long-term; new patients should not be started on 80 mg
- Multiple dose-ceiling interactions in elderly (amiodarone, amlodipine, verapamil) — atorvastatin is often a safer choice due to fewer CYP3A4 interaction-related dose limits
- In frail elderly over 85 or those with limited life expectancy: consider deprescribing — absolute benefit is small and pill burden significant (STOPP criteria v3)
- Evening dosing is important for simvastatin (unlike atorvastatin, which can be taken at any time)
- HEART PROTECTION STUDY: demonstrated benefit in secondary prevention regardless of baseline cholesterol level
Contraindications
- Active liver disease
- Pregnancy and breastfeeding
- Concurrent use of strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, ciclosporin)
Side effects
- Myalgia (most common)
- Rhabdomyolysis (rare — risk increased at 80 mg or with interacting drugs)
- Elevated transaminases
- New-onset diabetes
- Headache
Interactions
- Amiodarone (limit simvastatin to 20 mg/day — myopathy risk)
- Amlodipine (limit to 20 mg/day)
- Verapamil / diltiazem (limit to 10 mg/day)
- Clarithromycin / itraconazole (contraindicated — CYP3A4 inhibition causing myopathy/rhabdomyolysis)
- Colchicine (myopathy risk)
- Warfarin (modest INR increase)
Monitoring
- Lipid profile
- LFTs (baseline, 3 months)
- CK (if muscle symptoms)
- INR if on warfarin
Reference: BNFc; BNF 90; MHRA Drug Safety Update 2012 (simvastatin 80 mg); NICE NG238; Heart Protection Study; STOPP/START v3. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Framingham Risk Score · Cardiovascular Risk
- ACC/AHA Pooled Cohort Equations — ASCVD Risk · Cardiovascular Risk
- PREVENT Cardiovascular Risk Calculator (AHA/ACC 2023) · Cardiovascular Risk
- Reynolds Risk Score for Women · Cardiovascular Risk
- SCORE2 — 10-Year CVD Risk (Age 40–69) · Cardiovascular Risk
- SCORE2-OP — 5/10-Year CVD Risk (Age ≥ 70) · Cardiovascular Risk
Pathways